Effect of Spirnolactone in heart failure

Effect of spironolactone with doses 25 and 50 mg in patients with symptomatic Systolic Heart Failure and Ejection Fraction less than 40% on quality of life and Ability and Readmission in 6 months

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015010520563N1

Enrollment

100

Registered

2015-08-07

Start date

2014-12-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. congestive heart failure

Interventions

Intervention 1: one group of patients with a daily dose of 25 spironolactone tablets (control)for 6 month and all patients except spironolactone benefited from the same standard treatment for heart fa

Treatment - Drugs

one group of patients with a daily dose of 25 spironolactone tablets (control)for 6 month and all patients except spironolactone benefited from the same standard treatment for heart failure at dischar

group of patients with a daily dose of 50 spironolactone tablets ( case group) for 6 month and all patients except spironolactone benefited from the same standard treatment for heart failure at discha

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion critria: patient with systolic heart failure ? symptomatic ? EF<40 EXCLUSION critria:Known contraindications for spironolactone or prior documented intolerance to an aldosterone receptor antagonist ?Significant laboratory abnormalities (potassium = 5.1 mmol) ? Mental disorders suspected to interact with study outcome ?Pregnant women ? Significant renal dysfunction (creatinine . 1.8 mg/dL) ? Significant hypotension (blood pressure , 90 mmHg systolic and/or ,50 mmHg diastolic ? CRT or ICD

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ejection Fraction. Timepoint: At start of study and 6 month later. Method of measurement: Percent.;Functional capacity. Timepoint: At start of study and 6 month later. Method of measurement: 6 minute walk test { meter}.;Qulity of life. Timepoint: At start of study and 6 month later. Method of measurement: Minesutta Qulity of life qustionare{ score}.	—

Secondary

Measure	Time frame
Cr. Timepoint: at start. after 3 month. after 6 month. Method of measurement: mg/dL.;Potasium. Timepoint: at start. after 3 month. after 6 month. Method of measurement: mg/dL.;Hypotansion. Timepoint: at start. after 3 month. after 6 month. Method of measurement: mmHG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ahmad Reza Asare

Ahwaz Jundishapur University of Medical Science

dr.assareh@gmail.com+98 61 3222 8037

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026